Acceleron Pharma : Results of Operations and Financial Condition

Results of Operations and Financial Condition.

On April 29, 2021, Bristol Myers Squibb ('BMS') announced that net sales of REBLOZYL® (luspatercept-aamt) were approximately $112 million for the quarter ended March 31, 2021. As previously disclosed, under the collaboration agreement between Acceleron Pharma Inc. (the 'Company') and BMS for REBLOZYL, the Company is eligible to receive tiered royalty payments from BMS on net sales of REBLOZYL in the low-to-mid 20% range. The Company expects to report royalty revenue of approximately $22.4 million from net sales of REBLOZYL in the quarter ended March 31, 2021.

This preliminary unaudited revenue estimate is the responsibility of management and is subject to the completion of the Company's customary quarter-end financial closing procedures, including management's review and finalization, as well as review procedures by the Company's independent registered public accounting firm, which have not yet been completed. During the course of the Company's review process, items may be identified that would require it to make adjustments, which could result in material changes to the Company's preliminary unaudited estimated financial results. Consequently, this revenue estimate should not be viewed as a substitute for the Company's earnings release and the Quarterly Report on Form 10-Q for the quarter ended March 31, 2021.

The information contained in this Item is being furnished and shall not be deemed 'filed' for any purpose, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, regardless of any general incorporation language in any such filing.

2